KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Debt (2016 - 2024)

Historic Total Debt for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Q2 2024 value amounting to $494.8 million.

  • Biomarin Pharmaceutical's Total Debt changed N/A to $494.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $494.8 million, marking a year-over-year change of. This contributed to the annual value of $493.9 million for FY2023, which is 300126.84% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Total Debt of $494.8 million as of Q2 2024.
  • In the past 5 years, Biomarin Pharmaceutical's Total Debt registered a high of $494.8 million during Q2 2024, and its lowest value of $15.9 million during Q4 2022.
  • Moreover, its 5-year median value for Total Debt was $64.0 million (2022), whereas its average is $225.6 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Total Debt soared by 364290.0% in 2020, and later tumbled by 9158.11% in 2021.
  • Biomarin Pharmaceutical's Total Debt (Quarter) stood at $374.3 million in 2020, then plummeted by 87.11% to $48.2 million in 2021, then crashed by 66.98% to $15.9 million in 2022, then skyrocketed by 3001.27% to $493.9 million in 2023, then grew by 0.19% to $494.8 million in 2024.
  • Its Total Debt was $494.8 million in Q2 2024, compared to $494.4 million in Q1 2024 and $493.9 million in Q4 2023.